

## AttenTrex™

Contains ingredients promoting the drive required for attention and feeling energized, in a chewable tablet delivery with flexible dosing for the entire family\*



### Patient Profile†

- Inattentive, a lack of energy to spark attention
- Feeling sluggish and unable to get started on a task
- Seeking a more energetic mood


### Key Benefits

- Complete catecholamine pathway coverage combining precursor and cofactor support\*
- Chewable tablet delivery for flexible, customized dosing as needed
- Age specific suggested use, from 4 years old to adult
- Vegetarian ingredients with no artificial sweeteners or gluten

### Key Ingredients

L-tyrosine	<ul style="list-style-type: none"> <li>■ <b>Precursor to catecholamines</b> including dopamine, norepinephrine, and epinephrine<sup>1</sup></li> <li>■ Readily absorbed across the intestinal epithelium and blood-brain barrier</li> </ul>
Vitamins B6 and C	<ul style="list-style-type: none"> <li>■ <b>Active form</b> of vitamin B6 and C are important for the synthesis of dopamine and norepinephrine<sup>2,3*</sup></li> </ul>

### The Science




#### Catecholamines

A class of neurotransmitters responsible for many functions in the nervous and endocrine systems<sup>4</sup>

Catecholamines play an important role in mood, **energy**, memory, **attention**, cravings, and cognition<sup>5-9</sup>


#### Catecholamine Pathway



† Symptom depictions represent a possible presentation based on scientific information and claims found on this sheet, references provided on reverse.

# MORE SCIENCE BEHIND ATTENTREX

Figure 1. Sparking Attention




## Norepinephrine in the CNS (central nervous system)

Norepinephrine is crucial for stimulating attention and the state of wakefulness<sup>7,10\*</sup>

- Endogenous attention is the capacity to engage in a specific task, a single stimulus, or follow an instruction set<sup>11</sup> (Figure 1)
- Depletion of norepinephrine and other catecholamines results in inattentiveness, depleted energy, impulse control, and mood concerns<sup>5</sup>

**AttenTrex provides L-tyrosine and cofactors required for naturally producing norepinephrine, which supports feeling mentally prepared to spark attention and physical energy<sup>5\*</sup>**

Figure 2. The Building Blocks of Attention and Focus




## Unique catecholamines working together

PEA activity impacts TAAR receptors, reducing catecholamine reuptake and increasing norepinephrine in the synapse<sup>12</sup> (Figure 2)

- To avoid depletion, catecholaminergic neurons require adequate precursors like L-tyrosine and vitamins B6 and C
- Through TAAR receptor activation, PEA prolongs the activity of catecholamines like norepinephrine<sup>12</sup>

## Maximize your norepinephrine\*

- **Focus DL** directly supports PEA and sustained concentration to remain focused on accomplishing a goal over time<sup>13\*</sup>
- Paired together, **AttenTrex** and **Focus DL** provide complete support for sparking attention and sustaining focus through any task<sup>7-13</sup>



Item Number	Available Sizes	Serving Size
20060	60 Tablets	2 Tablets

## Meet more members of the chewable Trex family

Learn more at [www.neuroscienceinc.com/products/gaba-trex-chewable-tablets](http://www.neuroscienceinc.com/products/gaba-trex-chewable-tablets)

All NeuroScience products undergo rigorous third-party testing to guarantee label claims of each ingredient and the absence of heavy metals, pesticides, residual solvents, and microbes

1. Ng J, et al. *Nat Rev Neurol*. 2015;11:567-84.
2. Dakshinamurti K. *Ann NY Acad Sci*. 1990;585:128-44.
3. May J, et al. *Brain Res Bull*. 2013;90:35-42.
4. Eisenhofer G, et al. *Pharmacol Rev*. 2004;56(3):331-49.
5. Clark K and Neudoost B. *Front Neural Circuits*. 2014;8:33.
6. Blier P. *J Psychiatry Neurosci*. 2001;26 Suppl:S1-2.
7. Verhoeff N, et al. *Pharmacol Biochem Behav*. 2003;74(2):425-32.
8. Xing B, et al. *Brain Res*. 2016;1641(Pt B):217-33.
9. Blum K, et al. *Front Psychol*. 2014;5:919.
10. Berridge C, et al. *Sleep Med Rev*. 2012; 16(2): 187-197.
11. Dugue L, et al. *Sci Rep*. 2020;10(1):21274.
12. Ilrsted M, et al. *Webmedcentral*. 2014;4(9):1-15.
13. Kusaga A, et al. *Ann Neurol*. 2002;52:371-74.

\*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.